<DOC>
	<DOCNO>NCT02181504</DOCNO>
	<brief_summary>This safety efficacy study abicipar pegol patient neovascular age-related macular degeneration establish comparability Japanese non-Japanese .</brief_summary>
	<brief_title>A Study Abicipar Pegol Japanese Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ethnically Japanese Diagnosis wet agerelated macular degeneration least 1 eye Best correct visual acuity 20/32 20/320 study eye 20/200 good fellow eye Hypersensitivity , allergy , anaphylactic reaction iodine shellfish Cataract refractive surgery within last 3 month History vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>